Scholarlink

<p>Fibroblast growth factor receptor (FGFR) alterations are targetable in metastatic urothelial carcinoma (mUC). Identifying FGFR alterations currently requires tissue testing, which is limited by sample availability and cancer heterogeneity. Plasma circulating tumor DNA (ctDNA) offers a complementary testing strategy, but the added value of ctDNA relative to conventional FGFR alteration assessment remains unclear. Here, in a prospective, multicentre study, we show that ctDNA testing has high concordance with tissue FGFR testing and identifies additional actionable FGFR alterations. We profile plasma from 208 patients with mUC undergoing clinical FGFR tissue testing for erdafitinib eligibility. In evaluable baseline samples, FGFR alteration frequency is 26% in either tissue or ctDNA. Among 125 patients with baseline detected ctDNA and paired tissue results, FGFR status is concordant in 90%, and ctDNA has an 84% sensitivity for tissue-detected alterations while also identifying 7 additional cases. Serial plasma collections post-baseline further clarify FGFR status. In 21 patients who received erdafitinib after testing, the median progression-free survival is 7.5 months, and one patient with a ctDNA-exclusive FGFR alteration remained on erdafitinib for 33 months. Our results support clinical uptake of ctDNA FGFR testing in combination with tissue-based approaches in mUC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月27日

查看全文
  • David C. Müller,
  • Andrew J. Murtha,
  • Jack V. W. Bacon,
  • Maria Stephenson,
  • Connor Wells,
  • Carlos Vasquez-Rios,
  • Kimia Rostin,
  • Lisa Rebane,
  • Elena Schönlau,
  • Jussi Nikkola,
  • Nimira Alimohamed,
  • Naveen S. Basappa,
  • Daygen Finch,
  • Jenny J. Ko,
  • Jean-Michel Lavoie,
  • Lucia Nappi,
  • Krista Noonan,
  • Michael Ong,
  • Guliz Ozgun,
  • Sunil Parimi,
  • Maryam Soleimani,
  • Srikala S. Sridhar,
  • Paul Toren,
  • Eric Winquist,
  • Cecily Q. Bernales,
  • Melissa Koudjanian,
  • Jaskirat Atwal,
  • Emily Fung,
  • Laiba Khan,
  • Bryndan Eigl,
  • Dalia Othman,
  • Tarek A. Bismar,
  • Gang Wang,
  • Reem Merza,
  • Andreas I. Papadakis,
  • Alan Spatz,
  • Christian Kollmannsberger,
  • Corinne Maurice-Dror,
  • Matti Annala,
  • Kim N. Chi,
  • Gillian Vandekerkhove,
  • Alexander W. Wyatt,
  • Bernhard J. Eigl

摘要

Fibroblast growth factor receptor (FGFR) alterations are targetable in metastatic urothelial carcinoma (mUC). Identifying FGFR alterations currently requires tissue testing, which is limited by sample availability and cancer heterogeneity. Plasma circulating tumor DNA (ctDNA) offers a complementary testing strategy, but the added value of ctDNA relative to conventional FGFR alteration assessment remains unclear. Here, in a prospective, multicentre study, we show that ctDNA testing has high concordance with tissue FGFR testing and identifies additional actionable FGFR alterations. We profile plasma from 208 patients with mUC undergoing clinical FGFR tissue testing for erdafitinib eligibility. In evaluable baseline samples, FGFR alteration frequency is 26% in either tissue or ctDNA. Among 125 patients with baseline detected ctDNA and paired tissue results, FGFR status is concordant in 90%, and ctDNA has an 84% sensitivity for tissue-detected alterations while also identifying 7 additional cases. Serial plasma collections post-baseline further clarify FGFR status. In 21 patients who received erdafitinib after testing, the median progression-free survival is 7.5 months, and one patient with a ctDNA-exclusive FGFR alteration remained on erdafitinib for 33 months. Our results support clinical uptake of ctDNA FGFR testing in combination with tissue-based approaches in mUC.